Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).

Trial Details

NCT ID
NCT07360314
Phase
PHASE1
Sponsor
EMD Serono Research & Development Institute, Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • M7437
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Huntersville, North Carolina, United States|35.41069,-80.84285
  • Galveston, Texas, United States|29.30135,-94.7977
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Toronto, Canada|43.70643,-79.39864

Key Eligibility Criteria

  • Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants s…
  • For each tumor type, participants have received prior lines of therapy, where locally available:
  • Non-small cell lung cancer (nonsquamous or squamous)
  • Triple-negative breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →